FDA Formally Classifies SARS-CoV-2 Antibody Tests
Published Date: 6/26/2026
Rule
Summary
The FDA is officially putting the COVID-19 antibody (serology) test into a safer, easier-to-manage category called Class II, starting June 26, 2026. This change helps make sure the tests work well and are safe, while also making it simpler for companies to bring new and better tests to patients. If you’re a test maker or user, expect smoother rules and better access without extra costs or delays.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
SARS‑CoV‑2 Serology Reclassified to Class II
The FDA officially classified SARS‑CoV‑2 serology tests as Class II (special controls) effective June 26, 2026; the classification was applicable on May 5, 2023. As Class II devices, they are subject to premarket notification (section 510(k)) rather than automatic Class III premarket approval, and a De Novo-classified device can serve as a predicate for future 510(k) submissions.
New Special Controls and Emergency Duties
Manufacturers of SARS‑CoV‑2 serology tests must meet detailed special controls including labeling, multisite clinical and analytical studies, design verification/validation, software and cybersecurity documentation, lot‑level studies, and risk‑monitoring protocols. If FDA notifies manufacturers that characterized samples are available during certain events, testing must be performed within 30 days and results included in labeling within 60 days and retained in labeling for 3 years; FDA may request evaluations be submitted within 48 hours.
Tests Limited to Prescription Use
At the time of classification, SARS‑CoV‑2 serology tests are for prescription use only and must meet prescription labeling requirements under 21 CFR 809.10. This means these antibody tests are intended to be used under a healthcare provider's prescription rather than as over‑the‑counter direct‑to‑consumer tests.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16420, Guide To Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce; Guidance for Industry; Availability
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce." This guidance supersedes a previous guidance, entitled "Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables," issued in 2008, and is a final guidance to the draft guidance for industry entitled "Guide to Minimize Food Safety Hazards of Fresh-Cut Produce" issued in 2018. The guidance is intended to help manufacturers or processors of ready-to-eat fresh-cut produce that is not a low-moisture food comply with applicable requirements in our regulations on current good manufacturing practices for hazard analysis and risk-based preventive controls for human food.
2026-16353, Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. GDUFA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to authorize FDA to assess and collect fees to support human generic drug activities. The current legislative authority for GDUFA expires at the end of September 2027. At that time, new legislation will be required for FDA to continue to assess and collect generic drug user fees for future fiscal years. The FD&C Act directs FDA, following negotiations with the regulated industry and periodic consultations with other stakeholders, to present recommendations for reauthorization of the GDUFA program to the relevant Congressional committees, publish the recommendations in the Federal Register, provide for a period of 30 days for the public to provide written comments on such recommendations, and hold a meeting at which the public may present its views on such recommendations. FDA will then consider such public views and comments and revise such recommendations as necessary.
2026-16209, Radiology Devices; Reclassification of Digital Breast Tomosynthesis System
The FDA wants to change how digital breast tomosynthesis (DBT) systems are classified, moving them from a strict, high-level category (Class III) to a more flexible one (Class II) with special safety rules. This affects companies making these breast imaging devices, making it easier and faster to get them approved. Comments on this change are open until October 9, 2026, so stakeholders should act fast to share their thoughts!
Previous / Next Documents
Previous: 2026-12901, Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms
The FDA is officially classifying a computerized behavioral therapy device for fibromyalgia symptoms as a Class II device, meaning it meets safety and effectiveness standards with special controls. This change helps patients get easier access to this innovative treatment by reducing some regulatory hurdles. The new classification is effective June 26, 2026, and could speed up how quickly these devices reach the market without extra costs.
Next: 2026-12903, Medical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval System
The FDA has officially placed the breast implant suction retrieval system into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make the device safer and easier to get to patients without unnecessary delays. The new classification took effect on June 26, 2026, and could speed up innovation while keeping costs in check for makers and users.